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Background. The brain is deemed “immunologically privileged” due to 
sparse professional antigen-presenting cells and lymphatic drainage, and 
to the blood-brain barrier. Although the actual extent of this privilege is 
controversial, there is general consensus about the limited need in 
intracerebral neural grafts for immunosuppressive regimens comparable to 
those used in other cases of allotransplantation. This has led over the past 
fifteen years to the use of either short term or even no immunosuppression 
in most clinical trials with foetal neural transplant in patients with 
Parkinson’s and Huntington’s disease.  
Methodology/Principal Findings. We report biological demonstration of 
alloimmunisation without signs of rejection in four grafted patients out of 
13 studied during the course of a clinical trial involving fetal neural 
transplantation in patients with Huntington Disease. Biological, radiological 
and clinical demonstration of an ongoing rejection process was observed 
in a fifth transplanted patient. The rejection process was, however, fully 
reversible under immunosuppressive treatment and graft activity recovered 
within six months.  
Conclusions/significance. There had been, up to date, no report of 
documented cases that could have cast a doubt on those procedures. Our 
results underline the need for a reconsideration of the extent of the so-
called immune privilege of the brain and of the follow up protocols of 
patients with intracerebral grafts. It also suggests that some of the results 
obtained in past studies with foetal neural transplants may have been 
biased by an unrecognized immune response to donor cells. 
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Introduction 
Transplantation of cells and tissues to the mammalian brain and CNS has 
been clinically assessed for more than 15 years, in several hundred patients with 
Parkinson or Huntington Disease. Because the brain was considered differently 
than almost all other organs, in terms of the possibility of an immune response, 
little consideration has been given up to now either to the potential existence of 
adverse consequences of a rejection process, or even to the existence any sign 
of allo-immunisation in patients. The mechanisms underlying this privilege are 
diverse, and probably cumulative, and results from the blood– brain barrier, the 
absence of professional antigen-presenting cells in the brain and the sparse 
lymphatic drainage from the central nervous system (reviewed in ref. 1). 
Experimental studies in animal models have, however, now revealed that the 
previously held view that the brain was an absolute immunologically privileged 
site allowing indefinite survival without rejection of grafts of cells was wrong. 
Activated lymphocytes can cross the BBB, certain cells such as microglia may 
have an antigen presenting cell capacity and there is lymphatic drainage from the 
brain into the cervical lymph nodes. Thus, the brain should be regarded as a site 
where immune responses can occur, albeit in a modified form. Up to now, 
however, there had been no report of an immune rejection process following 
foetal neural grafting to the brain of a patient. We report here a first human case 
of characterized rejection, and a number of transplanted patients with biological 
signs of all-immunisation against the antigens of the foetal donors.  
Methods  
A phase II study looking for therapeutic efficacy of foetal neural grafts to the 
brain of patients with Huntington’s disease (“MIG-HD”, ref. NCT00190450) is 
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currently ongoing in Europe, following the promising results of a pilot study2,3,4. 
The original protocol has been approved by the CCPPRB of the Hospital Henri-
Mondor in Creteil on August 8, 2001. Additional protocols and modifications to 
the letter of information and informed consent related to the reported study were 
accepted by the same committee on May 17, 2005 and January 16, 2006. 
Specific information was given to patients, whose personal data are included in 
this paper and all signed and informed consent for publication. 
This protocol involves a temporary immunosuppressive therapy with 
cyclosporin A stopped during the first year after bilateral grafting, azathioprin and 
prednisolone progressively decreased then stopped over the following months. 
The present study has been organized as an ancillary to the main trial. It 
concerned 13 patients (table 1), who had received foetal neural transplants in two 
successive stereotaxic neurosurgical sessions –first aiming at the  right striatum, 
second at the left- three weeks to three months apart except in patient 2, in which 
a surgical complication (subdural hematoma) following the first graft precluded a 
second session.  
Assessment protocols and imaging methods have been described in 
referenced studies (3 and 4). As a potential source for subsequent controls, 
patient’s blood and foetal donor tissue were systematically taken and kept frozen, 
as part of the original protocol. Up to now, it had never been necessary to study 
those samples, which were defrozen for the present analysis in all 13 patients. 
Search for anti-HLA I and II antibodies against foetal donor antigens were not 
part of the original protocol (but are now an approved addition). They were 
carried out on blood samples, and in one case cerebrospinal fluid (patient 3), 
using classical techniques.    
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Results 
Fourteen months after grafting, one patient (patient 3) started to exhibit 
general alteration of clinical status with weight loss of 22 kg over three months, 
worsened choreic movements lateralised to the left side, gait disorders and falls. 
Brain MRI showed an ongoing encephalitic process with vasogenic oedema, 
extending from the striatum to the frontal cortex mostly on the right side (Figure 
1). Positron emission tomography with 18F-deoxyglucose revealed decreased 
metabolic activity in the same area of the right hemisphere (Figure 1), whereas 
striatal metabolism increased by about 50% on the left side, as commonly 
observed in the presence of functional grafts3,4.  
After ruling out an infection on the basis of the lack of alteration of blood 
cells count, a graft rejection was hypothesized. A humoral response was indeed 
documented with anti-HLA I –but not II– antibodies in the blood (6 out of 30, i.e. 
cytotoxicity equivalent to 20% for a panel of 30 total lymphocyte suspensions) 
and in the cerebrospinal fluid (2 out of 30, i.e. cytotoxicity equivalent to 7% of the 
panel tested). The antibodies (IgG) were specifically directed against A3 and A11 
class I HLAs. Control assay in a serum sample frozen immediately before 
surgery was negative for HLA antibodies, indicating post-operative occurrence of 
the specific B lymphocyte response. Biological demonstration of alloimmunisation 
against the graft tissues was provided by haplotyping preserved frozen samples 
from the three foetuses used for grafting, with HLA-A*3 allele in the foetus grafted 
on the right side, HLA-A*11 in one of the two foetuses grafted in the left striatum.   
Aggressive acute anti-inflammatory treatment associated to reinstatement 
of the original immunosuppressive regimen rapidly led to regression of MRI signs 
of encephalitis. General clinical status remained altered for 4 more months then 
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recovered, the patient regaining more than half of her lost weight. Anti-HLA I 
antibodies disappeared from blood and CSF samples. After 7 months of 
treatment, chorea lessened back to pre-rejection levels, while gait disorders and 
falls disappeared. The patient regained more than half of the lost weight. PET 
scan imaging then revealed the presence in the right striatum of two areas of 
increased metabolic activity (Figure 1) as compared not only to the 
hypometabolic state observed during the rejection episode, but also to 
preoperative values. After coregistration with the MRI, both areas suggest the 
presence of neural grafts. 
Alloimmunisation to donors’ antigens was sought in 12 other MIG-HD 
grafted patients followed up different times beyond the end of the period of 
immunosuppressive treatment. Four of them demonstrated alloimmunisation to 
one of the donors although none displayed either clinical or radiological signs of 
an ongoing rejection process (patients 2, 4, 5 and 11; Table 1). No specific 
pattern of alteration of blood cells counts could be identified in successive 
assessments over time that would differentiate the five alloimmunised patients 
(including the one with the ongoing rejection process) and the seven non-
immunised patients (see supplementary data). Because a search of 
alloimmunisation to foetal donor antigens was not part of the MIG-HD protocol 
before the identification of the rejection case reported here, it was not possible to 
determine the time of occurrence of HLA antibodies in the blood. It is interesting 
to mention, however, that one of the four positive patients (patient 11) had been 
transplanted less than six months before analysis as this shows that the humoral 
response to allo-antigens may occur under full immunosuppressive treatment, 
although it disappeared at a later time point, like in patient 3.  
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Discussion 
The main result of our study is the demonstration that a large proportion of 
patients who received intracerebral foetal neural grafts exhibited biological signs 
of allo-immunisation to donors’ antigens, in general a few months after 
interruption of the immunosuppressive treatment. In one patient, this was 
accompanied by overt clinical, radiological and biological signs of an ongoing 
immune rejection process; this process was, however, fully reversible under 
treatment. These results call for a reconsideration of results of previous foetal 
neural grafts trials in which a deleterious effect of potentially similar immune 
responses was not examined. They underline the need for careful follow up of 
patients and appropriate immunosuppressive treatment in future clinical trials.  
Our results show that foetal neural cells grafted to the brain may provoke a 
humoral response as other organ transplants5, with specific alloimmunisation to 
donors’ antigens in a significant proportion of patients. The role of the humoral 
response has been extensively studied in the pathogenesis of acute or 
hyperacute vascular rejection, but is now also demonstrated in chronic rejection. 
The appearance of HLA antibodies after transplantation is associated, in kidney, 
pancreas, heart and lung transplantation with poor transplant outcome and the 
occurrence of both acute and chronic rejection (review in ref.6). After kidney 
transplantation, the humoral response was generally detected before transplant 
failure7, suggesting that HLA antibodies could be responsible for transplant 
dysfunction. Previous studies have found wide variations in the percentage of 
patients with HLA antibodies after kidney transplantation, ranging between 12 
and 60 %. Our results are, thus, well in keeping with those obtained in other 
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organ transplants, indicating that the immunological privilege of the brain may not 
extend as much to the activation of a humoral response. There are, however, 
major differences between the consequences of that allo-immunisation in the 
brain as compared to other organs. It is worth noting, first, that the presence of 
anti-HLA antibodies was not accompanied in all except one of our cases by overt 
signs of graft rejection. Second, even in the one case in whom an ongoing 
rejection process was identified, full reversion of the deleterious process could be 
obtained under treatment, including a functional recovery of the graft.  This, 
together with previous evidence in animals8,9, showing in particular that triggering 
of an immune response may not lead to complete tissue rejection even in the 
presence of physiological signs, points to the existence of specific features of an 
immune response in the brain.   
Our results call for reconsideration of the results of past clinical trials with 
foetal neural grafts performed, for most of them, in patients with Parkinson’s 
disease. To our knowledge, there has been no systematic follow up of  possible 
immune responses to grafts up to now in those trials, and immunosuppressive 
regimens have been extremely diverse, ranging from a classical long term tri-
therapy10,11 down to no treatment altogether12, with various intermediate 
situations comparable to the one used in this study13,14.  What could have been 
the consequences of an inappropriate, or insufficiently maintained 
immunosuppressive regimen is but, at this point, a matter of speculation. 
Nevertheless, it is worth underlining the fact that at least in one large scale study 
a negative evolution of the results over time, following a first period of clinical 
improvement, was hypothetically related to the event of an otherwise 
undetermined immune response14. Also possibly relevant to our data is the 
appearance of major dyskinetic adverse effects in the long term following grafting 
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in patients with Parkinson’s disease12. Alloimmunisation to donors may indeed 
have contributed to those partially negative results and to the occurrence of 
delayed side-effects as, even in the absence of overt signs of a rejection process, 
effected neural grafts produce and elicit cytokine responses that may contribute 
to adverse functional effects observed in patients.  
Conclusions 
Our results clearly point to the fact that immune responses in the brain are 
complex, but cannot be ignored when it comes to repair strategies involving 
cellular transplants. New experimental studies are definitely needed in order to 
better comprehend and delineate the immunological privilege of the brain. The 
results of those experimental studies will allow us, in the future, to define more 
precisely the extent to which immunosuppressive regimens can be adapted to 
the specific case of intracerebral transplants. Until this redefinition is available, 
long term immunosuppressive treatment and thorough follow up of the 
immunological status of patients are likely indispensable. 
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Figure 1. Brain imaging of the rejection process in patient 3 and its 
reversion under treatment. Magnetic resonance imaging and metabolic activity 
using 18F-deoxyglucose before surgery (T0), during the rejection process (T1) 
and after 6 months of reinstated immunosuppressive treatment (T2) are shown 
separately (upper and middle panel, respectively), then co-registered (lower 
panel). The white arrow indicates the right striatum. The false colour scale shows 
levels of metabolic activities from lowest (min) to highest (max). 
H
AL author m
anuscript    inserm
-00108216, version 1
H
AL author m
anuscript    inserm
-00108216, version 1
12 
Table 1. Clinical characteristics of the 13 grafted patients tested for the 
presence of antibodies against foetal donors’ HLA I antigens. Results of 
evaluation scales for general capacity (TFC, total functional capacitance), motor 
symptoms (UHDRS, motor part of the Unified Huntington Disease Rating Scale) 
and cognitive functions (MDRS, Mattis Dementia Rating Scale) are indicated at 
the time of grafting. The situation of the immunosuppressive treatment is 
indicated at the time of analysis of antibodies, either in months (m) when they 
have been interrupted according to the protocol (see text), or else as “ongoing”. 
Serious adverse effects besides rejection (patient 3, in bold) were subdural 
hematomas (sdh, in two cases) and cerebral infection (inf, 1 case). For sake of 
anonymity, individual patients’ age, sex and number of CAG repeats are not 
shown. They were all between 39 and 55 years of age at the time of grafting; 
there were 5 women and 8 men; CAG repeats ranged between 42 and 49. 
 
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 
Disease duration 
(y) 
11 8 5 6 9 9 7 7 7 5 4 4 6 
TFC 10 10 11 11 9 7 10 13 8 9 10 12 13 
UHDRS 55 61 28 36 37 64 32 23 64 26 50 28 15 
MDRS 111 120 125 12
4 
12
2 
13
3 
12
2 
143 127 122 135 132 139 
AC HLA I - + + + + - - - - - + - - 
Cyclosporin  
A (m) 
9 13 9 9 6 7 7 7 ongoing 
 
ongoing 
 
6 6 ongoing 
Imurel/solupred 
(m) 
13 12 10 12 12 17 12 8 ongoing 
 
ongoing ongoing 
 
12 ongoing 
Adverse effects - sdh Rejection - - - - - - inf - sdh - 
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